HIV and tuberculosis: A deadly human syndemic

Clinical Microbiology Reviews

Volumn 24, Issue 2, 2011, Pages 351-376

  Kwan, Candice ^a   Ernst, J D ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETHAMBUTOL; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; THIOACETAZONE; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ADAPTIVE IMMUNITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL TRANSMISSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG METABOLISM; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY; INFECTION CONTROL; INFECTION RISK; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MOLECULAR INTERACTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUTROPENIA; PATHOGENESIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM SMEAR; SURVIVAL RATE; T CELL DEPLETION; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; URBAN POPULATION; UVEITIS; VIRUS TRANSMISSION;

COMMUNICABLE DISEASE CONTROL; COMORBIDITY; HIV INFECTIONS; HUMANS; INCIDENCE; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79955059280     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00042-10     Document Type: Review

References (273)

1. Aabye, M.G., et al. 2009. The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. PLoS One 4:e4220.
2. Abdool Karim, S.S., G.J. Churchyard, Q. Abdool Karim, and S.D. Lawn. 2009. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374:921-933.
3. Abdool Karim, S.S., et al. 2010. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362:697-706.
4. Aberg, J.A., et al. 2009. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49:651-681.
5. Abgrall, S., P. Del Giudice, G. Melica, and D. Costagliola. 2010. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. AIDS 24:763-771.
6. Abouya, L., et al. 1995. Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Côte d'Ivoire. Tuber. Lung Dis.76:436-440.
7. Ackah, A.N., et al. 1995. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 345:607-610.
8. Ahmed, A.B., et al. 2007. The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999-2003. Thorax 62:672-676.
9. Aichelburg, M.C., et al. 2009. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48:954-962.
10. Aiken, C., J. Konner, N.R. Landau, M.E. Lenburg, and D. Trono. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864.
11. Alonso Rodríguez, N., et al. 2009. Transmission permeability of tuberculosis involving immigrants, revealed by a multicentre analysis of clusters. Clin. Microbiol. Infect. 15:435-442.
12. Andrews, J.R., et al. 2008. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J. Infect. Dis. 198:1582-1589.
13. Badri, M., R. Ehrlich, R. Wood, T. Pulerwitz, and G. Maartens. 2001. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int. J. Tuberc. Lung Dis. 5:225-232.
14. Badri, M., D. Wilson, and R. Wood. 2002. Effect of highly active antiretro-viral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359:2059-2064.
15. Barnes, P.F., A.B. Bloch, P.T. Davidson, and D.E. Snider. 1991. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650.
16. Bartlett, J.A., J. Hornberger, A. Shewade, M. Bhor, and R. Rajagopalan. 2009. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings. J. Int. Assoc. Physicians AIDS Care 8:253-268.
17. Bartlett, J.G., P.G. Auwaerter, and P. Pham. 2010. Johns Hopkins POC-IT Center HIV guide. Johns Hopkins University, Baltimore, MD. http://www.hopkins-hivguide.org.
18. Bartlett, J.G., P.G. Auwaerter, and P.A. Pham. 2010. Johns Hopkins POC-IT Center ABX guide: diagnosis & treatment of infectious diseases, 2nd ed. Jones & Bartlett, Sudbury, MA. http://hopkins-abxguide.org/.
19. Basu, S., et al. 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370:1500-1507.
20. Batungwanayo, J., et al. 1992. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am. Rev. Respir. Dis. 146:53-56.
21. Bekker, L.G., and R. Wood. 2010. The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity. Clin. Infect. Dis. 50:S208-S214.
22. Blaak, H., et al. 2000. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc. Natl. Acad. Sci. U. S. A 97:1269-1274.
23. Blanc, F.-X., et al. 2010. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis, abstr. THLBB0106. International AIDS Conference, Vienna, Austria.
24. Blythe, M.J., et al. 2007. An analysis of the epitope knowledge related to mycobacteria. Immunome Res. 3:10.
25. Bocchino, M., B. Bellofiore, A. Matarese, D. Galati, and A. Sanduzzi. 2009. IFN-gamma release assays in tuberculosis management in selected high-risk populations. Expert Rev. Mol. Diagn. 9:165-177.
26. Boehme, C.C, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015.
27. Borgdorff, M.W., M.A. Behr, N.J. Nagelkerke, P.C. Hopewell, and P.M. Small. 2000. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int. J. Tuberc. Lung Dis. 4:287-294.
28. Borgdorff, M.W., et al. 2010. Progress towards tuberculosis elimination: secular trend, immigration and transmission. Eur. Respir. J. 36:339-347.
29. Boulanger, C, et al. 2009. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49:1305-1311.
30. Boulle, A., et al. 2008. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercu-lar therapy. JAMA 300:530-539.
31. Brainard, D.M., et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J. Clin. Pharmacol., in press.
32. Brenchley, J.M., et al. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112:2826-2835.
33. Bruns, H., et al. 2009. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest. 119:1167-1177.
34. Burman, W.J., and B.E. Jones. 2003. Clinical and radiographic features of HIV-related tuberculosis. Semin. Respir. Infect. 18:263-271.
35. Busi Rizzi, E., V. Schinina, F. Palmieri, E. Girardi, and C. Bibbolino. 2004. Cavitary pulmonary tuberculosis HIV-related. Eur. J. Radiol. 52:170-174.
36. Cain, K.P., et al. 2010. An algorithm for tuberculosis screening and diagnosis in people with HIV. N. Engl. J. Med. 362:707-716.
37. Carvalho, A.C, et al. 2001. Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am. J. Respir. Crit. Care Med. 164:2166-2171.
38. Cattamanchi, A., et al. 2008. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 133:875-880.
39. CDC. 1991. Epidemiologic notes and reports of nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons-Florida and New York, 1988-1991. MMWR Morb. Mortal. Wkly. Rep. 40:585-591.
40. CDC. 2005. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Morb. Mortal. Wkly. Rep. 54:1-141.
41. CDC. 2007. Managing drug interactions in the treatment of HIV-related tuberculosis. CDC, Atlanta, GA. http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm.
42. CDC. 1993. Outbreak of multidrug-resistant tuberculosis at a hospital- New York City, 1991. MMWR Morb. Mortal. Wkly. Rep. 42:427-433.
43. CDC. 2006. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR Recommend. Rep. 55(RR-9):1-44.
44. CDC. 1992. Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system-New York, 1991. MMWR Morb. Mortal. Wkly. Rep. 41:507-509.
45. CDC. 1993. Tuberculosis morbidity-United States, 1992. MMWR Morb. Mortal. Wkly. Rep. 42:696-697, 703-704.
46. Charalambous, S., et al. 2008. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int. J. Tuberc. Lung Dis. 12: 942-948.
47. Chaudhry, A., et al. 2005. The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J. Immunol. 175:4566-4574.
48. Chaudhry, A., et al. 2009. HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. J. Immunol. 183:2415-2424.
49. Chen, C.Y., et al. 2009. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5:e1000392.
50. Cho, S., et al. 2000. Antimicrobial activity of MHC class I-restricted CD8 + T cells in human tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 97:12210-12215.
51. Clark, M., P. Riben, and E. Nowgesic. 2002. The association of housing density, isolation and tuberculosis in Canadian First Nations communities. Int. J. Epidemiol. 31:940-945.
52. Clerici, M., et al. 1989. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J. Clin. Invest. 84:1892-1899.
53. Cohen, K., and G. Meintjes. 2010. Management of individuals requiring antiretroviral therapy and TB treatment. Curr. Opin. HIV AIDS 5:61-69.
54. Colebunders, R., and I. Bastian. 2000. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 4:97-107.
55. Colebunders, R., et al. 2006. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int. J. Tuberc. Lung Dis. 10:946-953.
56. Collins, K. R., M. E. Quińones-Mateu, Z. Toossi, and E. J. Arts. 2002. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev. 4:165-176.
57. Cooper, A.M., et al. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247.
58. Corbett, E.L., et al. 2009. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int. J. Tuberc. Lung Dis. 13:1231-1237.
59. Corbett, E.L., et al. 2007. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 4:e22.
60. Corbett, E.L., et al. 2004. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am. J. Respir. Crit. Care Med. 170:673-679.
61. Corbett, E.L., and K.M. De Cock. 2001. The clinical significance of interactions between HIV and TB: more questions than answers. Int. J. Tuberc. Lung Dis. 5:205-207.
62. Corbett, E.L., B. Marston, G.J. Churchyard, and K.M. De Cock. 2006. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367:926-937.
63. Corbett, E.L., et al. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
64. Corbett, E.L., et al. 2010. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull. World Health Organ. 88:13-21.
65. Cruciani, M., M. Malena, O. Bosco, G. Gatti, and G. Serpelloni. 2001. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin. Infect. Dis. 33:1922-1930.
66. Cunningham, R., F. Sabin, S. Sugiyama, and J. Kindwald. 1925. Role of the monocyte in tuberculosis. Bull. Johns Hopkins Hosp. 37:231-278.
67. Daley, C.L., J.A. Hahn, A.R. Moss, P.C. Hopewell, and G.F. Schecter. 1998. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am. J. Respir. Crit. Care Med. 157:19-22.
68. Daley, C.L., et al. 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N. Engl. J. Med. 326:231-235.
69. Da Silva, R.M., L. da Rosa, and R.N. Lemos. 2006. Radiographic alterations in patients presenting human immunodeficiency virus/tuberculosis coinfection: correlation with CD4+ T cell counts. J. Bras. Pneumol. 32: 228-233. (In Portugese.)
70. Day, J.H., et al. 2004. Does tuberculosis increase HIV load? J. Infect. Dis. 190:1677-1684.
71. DeRiemer, K., L.M. Kawamura, P.C. Hopewell, and C.L. Daley. 2007. Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics. Am. J. Respir. Crit. Care Med. 176:936-944.
72. Desalu, O., et al. 2009. Impact of immunosuppression on radiographic features of HIV related pulmonary tuberculosis among Nigerians. Turk. Thorac. J. 11:112-116.
73. Desvignes, L., and J.D. Ernst. 2009. Interferon-gamma-responsive nonhe-matopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity 31:974-985.
74. Dheda, K., F.C. Lampe, M.A. Johnson, and M.C. Lipman. 2004. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J. Infect. Dis. 190:1670-1676.
75. Dheda, K., R. V.Z. Smit, M. Badri, and M. Pai. 2009. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr. Opin. Pulm. Med. 15:188-200.
76. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC.
77. Diedrich, C.R., et al. 2010. Reactivation of latent tuberculosis in cynomol-gus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5:e9611.
78. Divangahi, M., et al. 2008. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J. Immunol. 181:7157-7165.
79. Doitsh, G., et al. 2010. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143:789-801.
80. Duh, E. J., W.J. Maury, T.M. Folks, A.S. Fauci, and A.B. Rabson. 1989. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc. Natl. Acad. Sci. U. S. A. 86:5974-5978.
81. Dye, C., and B.G. Williams. 2010. The population dynamics and control of tuberculosis. Science 328:856-861.
82. Egwaga, S.M., et al. 2006. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 20:915-921.
83. Elliott, J.H., et al. 2009. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis. 200:1736-1745.
84. El-Sadr, W.M., and S.J. Tsiouris. 2008. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin. Respir. Crit. Care Med. 29: 525-531.
85. Elsaesser, H., K. Sauer, and D. G. Brooks. 2009. IL-21 is required to control chronic viral infection. Science 324:1569-1572.
86. Emmelkamp, J.M., and J.K. Rockstroh. 2007. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur. J. Med. Res. 12:409-417.
87. Escombe, A.R., et al. 2008. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med. 5:e188.
88. Escombe, A.R., et al. 2007. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin. Infect. Dis. 44:1349-1357.
89. Escombe, A.R., et al. 2007. Natural ventilation for the prevention of airborne contagion. PLoS Med. 4:e68.
90. Espinal, M.A., et al. 2000. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet 355: 275-280.
91. Espinal, M.A., A.L. Reingold, E. Koenig, M. Lavandera, and S. Sanchez. 1995. Screening for active tuberculosis in HIV testing centre. Lancet 345: 890-893.
92. Fennelly, K.P. 2007. Variability of airborne transmission of Mycobacterium tuberculosis: implications for control of tuberculosis in the HIV era. Clin. Infect. Dis. 44:1358-1360.
93. Fennelly, K.P., et al. 2004. Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness. Am. J. Respir. Crit. Care Med. 169:604-609.
94. Ferwerda, G., et al. 2005. NOD2 and Toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 1:279- 285.
95. Flynn, J. L., et al. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254.
96. French, M.A., and M.A. French. 2009. HIV/AIDS. Immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 48:101-107.
97. French, M.A., P. Price, and S. F. Stone. 2004. Immune restoration disease after antiretroviral therapy. AIDS 18:1615-1627.
98. Frieden, T.R., P.I. Fujiwara, R.M. Washko, and M.A. Hamburg. 1995. Tuberculosis in New York City-turning the tide. N. Engl. J. Med. 333: 229-233.
99. Frieden, T. R., et al. 1996. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 276: 1229-1235.
100. Frieden, T.R., T. R. Sterling, S.S. Munsiff, C. J.Watt, and C.Dye.2003.Tuberculosis. Lancet 362:887-899.
101. Friedman, L.N., M.T. Williams, T.P. Singh, and T.R. Frieden. 1996. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N. Engl. J. Med. 334:828-833.
102. Frohlich, A., et al. 2009. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324:1576-1580.
103. Gallant, J.E., and A.H. Ko. 1996. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 22:671-682.
104. Gandhi, N.R., et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
105. Gandhi, N.R., et al. 2010. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am. J. Respir. Crit. Care Med. 181:80-86.
106. Garcia, G.F., A.S. Moura, C.S. Ferreira, and M.O. da Costa Rocha. 2007. Clinical and radiographic features of HIV-related pulmonary tuberculosis according to the level of immunosuppression. Rev. Soc. Bras. Med. Trop. 40:622-626.
107. Garrus, J.E., et al. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65.
108. Garzino-Demo, A., et al. 1999. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc. Natl. Acad. Sci. U. S. A. 96:11986-11991.
109. Geldmacher, C, et al. 2010. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J. Exp. Med. 207:2869-2881.
110. Geldmacher, C, et al. 2008. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J. Infect. Dis. 198:1590-1598.
111. Geng, E., B. Kreiswirth, J. Burzynski, and N.W. Schluger. 2005. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. JAMA 293:2740-2745.
112. Getahun, H., C. Gunneberg, R. Granich, and P. Nunn. 2010. HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 50:S201-S207.
113. Girardi, E., et al. 2004. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur. Respir. J. 24:11-17.
114. Girardi, E., et al. 2005. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin. Infect. Dis. 41:1772-1782.
115. Glocker, E. O., et al. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727-1735.
116. Glynn, J. R., et al. 2010. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J. Infect. Dis. 201:704-711.
117. Goletti, D., et al. 1996. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J. Immunol. (Baltimore) 157:1271-1278.
118. Greenberg, S. D., et al. 1994. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 193:115-119.
119. Haase, A. T. 1999. Population biology of HIV-1 infection: viral and CD4 + T cell demographics and dynamics in lymphatic tissues. Annu. Rev. Immunol. 17:625-656.
120. Haase, A.T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223.
121. Haddow, L.J., M.-Y. S. Moosa, and P.J. Easterbrook. 2010. Validation of a published case definition for tuberculosis-associated immune reconstitu-tion inflammatory syndrome. AIDS 24:103-108.
122. Hammond, A.S., et al. 2008. Mycobacterial T cell responses in HIV-infected patients with advanced immunosuppression. J. Infect. Dis. 197: 295-299.
123. Harries, A.D., et al. 2001. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 357:1519-1523.
124. Harries, A.D., R. Zachariah, and S.D. Lawn. 2009. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int. J. Tuberc. Lung Dis. 13:6-16.
125. Hazenberg, M.D., D. Hamann, H. Schuitemaker, and F. Miedema. 2000. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat. Immunol. 1:285-289.
126. Hellerstein, M., et al. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89.
127. Hellerstein, M.K., et al. 2003. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 112:956-966.
128. Holtz, T.H. 2007. XDR-TB in South Africa: revised definition. PLoS Med. 4:e161.
129. Horsburgh, C.R. 2004. Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. 350:2060-2067.
130. Humphreys, I. R., et al. 2006. A role for dendritic cells in the dissemination of mycobacterial infection. Microbes Infect. 8:1339-1346.
131. Iannello, A., et al. 2010. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J. Immunol. 184:114-126.
132. Iannello, A., et al. 2008. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts. Viral Immunol. 21:385-388.
133. Jamieson, C, P. G. McCaffrey, A. Rao, and R. Sen. 1991. Physiologic activation of T cells via the T cell receptor induces NF-kappa B. J. Immunol. 147:416-420.
134. Janssens, J. P., and H. L. Rieder. 2008. An ecological analysis of incidence of tuberculosis and per capita gross domestic product. Eur. Respir. J. 32:1415-1416.
135. Jenny-Avital, E. R., and K. Joseph. 2009. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin. Infect. Dis. 48:1471-1474.
136. Jindani, A., A. J. Nunn, and D. A. Enarson. 2004. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364:1244-1251.
137. Jones, B. E., et al. 1993. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am. Rev. Respir. Dis. 148:1292-1297.
138. Joosten, S. A., et al. 2010. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 6:e1000782.
139. Joseph, P., et al. 2006. Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS 20:415-418.
140. Jouanguy, E., et al. 2000. In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J. Clin. Invest. 105: 1429-1436.
141. Jouanguy, E., et al. 1997. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J. Clin. Invest. 100:2658-2664.
142. Kalsdorf, B., et al. 2009. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am. J. Respir. Crit. Care Med. 180:1262-1270.
143. Kaplan, J.E., et al. 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend. Rep. 58:1-207.
144. Kawooya, V.K., M. Kawooya, and A. Okwera. 2000. Radiographic appearances of pulmonary tuberculosis in HIV-1 seropositive and seronegative adult patients. East Afr. Med. J. 77:303-307.
145. Keiper, M.D., M. Beumont, A. Elshami, C.P. Langlotz, and W.T. Miller. 1995. CD4 T lymphocyte count and the radiographic presentation of pulmonary tuberculosis. A study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 107:74-80.
146. Kenyon, T.A., et al. 2002. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int. J. Tu-berc. Lung Dis. 6:843-850.
147. Khan, F.A., et al. 2010. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin. Infect. Dis. 50:1288-1299.
148. Kinoshita, S., B.K. Chen, H. Kaneshima, and G.P. Nolan. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95:595-604.
149. Kinter, A.L., et al. 1996. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. U. S. A. 93:14076-14081.
150. Komanduri, K.V., et al. 2001. Direct measurement of CD4+ and CD8 + T-cell responses to CMV in HIV-1-infected subjects. Virology 279:459-470.
151. Korenromp, E.L., F. Scano, B.G. Williams, C. Dye, and P. Nunn. 2003. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin. Infect. Dis. 37:101-112.
152. Lawn, S.D., M. Badri, and R. Wood. 2005. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19:2109-2116.
153. Lawn, S.D., L.-G. Bekker, and R.F. Miller. 2005. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 5:361-373.
154. Lawn, S.D., and L.G. Bekker. 2009. Co-pathogenesis of tuberculosis and HIV, p. 96-106. In H. S. Schaaf et al. (ed.), Tuberculosis: a comprehensive clinical reference. Saunders-Elsevier, Oxford, United Kingdom.
155. Lawn, S. D., et al. 2006. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin. Infect. Dis. 42:1040-1047.
156. Lawn, S.D., and G. Churchyard. 2009. Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4:325-333.
157. Lawn, S. D., L. Myer, D. Edwards, L.-G. Bekker, and R. Wood. 2009. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23:1717-1725.
158. Lawn, S.D., and R. Wood. 2007. When should antiretroviral treatment be started in patients with HIV-associated tuberculosis in South Africa? S. Afr. Med. J. 97:412, 414-415.
159. Leidl, L., et al. 2010. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur. Respir. J. 35:619-626.
160. Leung, A.N., et al. 1996. Pulmonary tuberculosis: comparison of CT findings in HIV-seropositive and HIV-seronegative patients. Radiology 198: 687-691.
161. Li, J., S.S. Munsiff, C.R. Driver, and J. Sackoff. 2005. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin. Infect. Dis. 41:83-91.
162. Lin, C.Y., et al. 2009. Aetiology of cavitary lung lesions in patients with HIV infection. HIV Med. 10:191-198.
163. Lonnroth, K., et al. 2010. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375:1814-1829.
164. Lonnroth, K., E. Jaramillo, B.G. Williams, C. Dye, and M. Raviglione. 2009. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc. Sci. Med. 68:2240-2246.
165. Loudon, R.G., and S.K. Spohn. 1969. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 99:109-111.
166. Ma, C.S., et al. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205:1551-1557.
167. MacPherson, D.W., et al. 2009. Population mobility, globalization, and antimicrobial drug resistance. Emerg. Infect. Dis. 15:1727-1732.
168. Manas, E., et al. 2004. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count. Int. J. Tuberc. Lung Dis. 8:451-457.
169. Manosuthi, W., S. Chottanapand, S. Thongyen, A. Chaovavanich, and S. Sungkanuparph. 2006. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 43:42-46.
170. Manosuthi, W., W. Mankatitham, A. Lueangniyomkul, S. Chimsuntorn, and S. Sungkanuparph. 2008. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 9:294-299.
171. Manosuthi, W., et al. 2009. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcrip-tase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin. Infect. Dis. 48:1752-1759.
172. Manosuthi, W., et al. 2009. Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 23:2467-2471.
173. Marais, S., R.J. Wilkinson, D.J. Pepper, and G. Meintjes. 2009. Management of patients with the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep. 6:162-171.
174. Martínez-Lirola, M., et al. 2008. Advanced survey of tuberculosis transmission in a complex socioepidemiologic scenario with a high proportion of cases in immigrants. Clin. Infect. Dis. 47:8-14.
175. Mase, S.R., et al. 2007. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis. 11:485-495.
176. Matloubian, M., R.J. Concepcion, and R. Ahmed. 1994. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056-8063.
177. Mazurek, M., et al. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recommend. Rep. 59:1-25.
178. McIlleron, H., G. Meintjes, W.J. Burman, and G. Maartens. 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196(Suppl. 1):S63-S75.
179. Means, T.K., et al. 1999. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 163:3920-3927.
180. Mehandru, S., et al. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200:761-770.
181. Meintjes, G., et al. 2008. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 8:516-523.
182. Meintjes, G., H. Rabie, R.J. Wilkinson, and M.F. Cotton. 2009. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin. Chest Med. 30:797-810.
183. Meintjes, G., et al. 2009. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin. Infect. Dis. 48:667-676.
184. Meintjes, G., et al. 2008. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 178:1083-1089.
185. Meintjes, G., et al. 2009. Randomized placebo-controlled trial of predni-sone for the TB immune reconstitution inflammatory syndrome, abstr. 34. Abstr. Conf. Retrovir. Oppor. Infect. 2009, Montreal, Canada.
186. Menzies, D., et al. 2009. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 6:e1000146.
187. Middelkoop, K., et al. 2008. Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin. Infect. Dis. 47:349-355.
188. Milburn, H.J. 2001. Primary tuberculosis. Curr. Opin. Pulm. Med. 7:133- 141.
189. Miller, E.A., and J.D. Ernst. 2009. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J. Clin. Invest. 119:1079- 1082.
190. Milner, J.D., et al. 2008. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-776.
191. Minion, J., E. Leung, D. Menzies, and M. Pai. 2010. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 10:688-698.
192. Minion, J., and M. Pai. 2010. Expanding the role of the microscopic observation drug susceptibility assay in tuberculosis and HIV management. Clin. Infect. Dis. 50:997-999.
193. Modi, W.S., et al. 2006. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV type 1 transmission and AIDS disease progression. Am. J. Hum. Genet. 79:120-128.
194. Mogues, T., M.E. Goodrich, L. Ryan, R. LaCourse, and R.J. North. 2001. The relative importance of T cell subsets in immunity and immunopathol-ogy of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193:271-280.
195. Monkongdee, P., et al. 2009. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 180:903-908.
196. Moore, D.A., et al. 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355:1539-1550.
197. Morris, L., et al. 2003. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J. Infect. Dis. 187:1967-1971.
198. Mukadi, Y.D., D. Maher, and A. Harries. 2001. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 15:143-152.
199. Mukadi, Y.D., et al. 1997. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Côte d'Ivoire. AIDS 11:1151-1158.
200. Mwandumba, H.C., et al. 2004. Mycobacterium tuberculosis resides in nonacidified vacuoles in endocytically competent alveolar macrophages from patients with tuberculosis and HIV infection. J. Immunol. 172:4592-4598.
201. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
202. Odhiambo, J.A., et al. 1999. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am. J. Public Health 89:1078-1082.
203. Okwera, A., et al. 1994. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 344:1323-1328.
204. Okwera, A., et al. 2006. Comparison of intermittent ethambutol with rifam-picin-based regimens in HIV-infected adults with PTB, Kampala. Int. J. Tuberc. Lung Dis. 10:39-44.
205. Osborn, L., S. Kunkel, and G.J. Nabel. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc.Natl.Acad.Sci. U.S.A. 86:2336-2340.
206. Palaci, M., et al. 2007. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J. Clin. Microbiol. 45:4064-4066.
207. Paolo, W.F., and J.D. Nosanchuk. 2004. Tuberculosis in New York city: recent lessons and a look ahead. Lancet Infect. Dis. 4:287-293.
208. Pastores, S.M., D.P. Naidich, C.P. Aranda, G. McGuinnes, and W.N. Rom. 1993. Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest 103: 1433-1437.
209. Patel, R.B., and T.F. Burke. 2009. Urbanization-an emerging humanitarian disaster. N. Engl. J. Med. 361:741-743.
210. Perlman, D.C., et al. 1997. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin. Infect. Dis. 25:242-246.
211. Perlman, D.C., C.C. Leung, and W.W. Yew. 2009. Diagnosing tuberculosis in patients with HIV: do we know enough? Am. J. Respir. Crit. Care Med. 180:800-801.
212. Peto, H.M., R.H. Pratt, T.A. Harrington, P.A. LoBue, and L.R. Armstrong. 2009. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin. Infect. Dis. 49:1350-1357.
213. Philips, J.A., M.C. Porto, H. Wang, E.J. Rubin, and N. Perrimon. 2008. ESCRT factors restrict mycobacterial growth. Proc. Natl. Acad. Sci. U. S. A. 105:3070-3075.
214. Post, F.A., R. Wood, and G.P. Pillay. 1995. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuber. Lung Dis. 76:518-521.
215. Randhawa, P.S. 1990. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 22:153-155.
216. Reddy, K.P., et al. 2010. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin. Infect. Dis. 50:988-996.
217. Reid, M.J.A., and N.S. Shah. 2009. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect. Dis. 9:173-184.
218. Rieder, H. 2005. Annual risk of infection with Mycobacterium tuberculosis. Eur. Respir. J. 25:181-185.
219. Rieder, H.L., G.M. Cauthen, G.W. Comstock, and D.E. Snider. 1989. Epidemiology of tuberculosis in the United States. Epidemiol. Rev. 11:79-98.
220. Sabin, F.R., and C.A. Doan. 1927. The relation of monocytes and clas-matocytes to early infection in rabbits with bovine tubercle bacilli. J. Exp. Med. 46:627-644.
221. Sadek, M.I., E. Sada, Z. Toossi, S.K. Schwander, and E.A. Rich. 1998. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am. J. Respir. Cell Mol. Biol. 19:513-521.
222. Sanguanwongse, N., et al. 2008. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J. Acquir. Immune Defic. Syndr. 48:181-189.
223. Santoro-Lopes, G., A.M. de Pinho, L.H. Harrison, and M. Schechter. 2002. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin. Infect. Dis. 34:543-546.
224. Saukkonen, J.J., et al. 2002. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect. Immun. 70:1684-1693.
225. Schiffer, J.T., and T.R. Sterling. 2007. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J. Acquir. Immune Defic. Syndr. 44:229-234.
226. Scriba, T.J., et al. 2008. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J. Immunol. 180:1962-1970.
227. Selwyn, P.A., et al. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
228. Shafer, R.W., and B.R. Edlin. 1996. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin. Infect. Dis. 22:683-704.
229. Shafer, R.W., D.S. Kim, J.P. Weiss, and J.M. Quale. 1991. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine 70:384-397.
230. Shelburne, S.A., M. Montes, and R.J. Hamill. 2006. Immune reconstitu-tion inflammatory syndrome: more answers, more questions. J. Antimicrob. Chemother. 57:167-170.
231. Slutkin, G., J. Leowski, and J. Mann. 1988. The effects of the AIDS epidemic on the tuberculosis problem and tuberculosis programmes. Bull. Int. Union Tuberc. Lung Dis. 63:21-24.
232. Small, P.M., and M. Pai. 2010. Tuberculosis diagnosis-time for a game change. N. Engl. J. Med. 363:1070-1071.
233. Smith, R.L., K. Yew, K.A. Berkowitz, and C.P. Aranda. 1994. Factors affecting the yield of acid-fast sputum smears in patients with HIV and tuberculosis. Chest 106:684-686.
234. Sonnenberg, P., et al. 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191:150-158.
235. Sonnenberg, P., et al. 2001. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358:1687-1693.
236. Steingart, K.R., et al. 2006. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect. Dis. 6:664-674.
237. Stenger, S., et al. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:121-125.
238. Stenger, S., et al. 1997. Differential effects of cytolytic T cell subsets on intracellular infection. Science 276:1684-1687.
239. Sterling, T.R., P.A. Pham, and R.E. Chaisson. 2010. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin. Infect. Dis. 50: S223-S230.
240. Stumptner-Cuvelette, P., et al. 2001. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. U.S.A. 98:12144-12149.
241. Sutherland, R., et al. 2006. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 20:821-829.
242. Syed Ahamed Kabeer, B., B. Raman, A. Thomas, V. Perumal, and A. Raja. 2010. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5:e9051.
243. Tabarsi, P., et al. 2009. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J. Int. AIDS Soc. 12:14.
244. Tailleux, L., et al. 2003. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197:121-127.
245. Toossi, Z. 2003. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J. Infect. Dis. 188:1146-1155.
246. Toossi, Z., et al. 2001. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin. Exp. Immunol. 123:233-238.
247. Toossi, Z., J.G. Sierra-Madero, R.A. Blinkhorn, M.A. Mettler, and E.A. Rich. 1993. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. J. Exp. Med. 177:1511-1516.
248. UNAIDS. 2009. AIDS epidemic update: November 2009. UNAIDS, Geneva, Switzerland.
249. UNAIDS. 2008. UNAIDS report on the global AIDS epidemic 2008. UNAIDS, Geneva, Switzerland. http://data.unaids.org/pub/GlobalReport/2008/JC1511_GR08_ExecutiveSummary_en.pdf.
250. UNFPA. 2007. State of the world population 2007: unleashing the potential of urban growth. United Nations Population Fund, Geneva, Switzerland.
251. van der Wel, N., et al. 2007. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129:1287-1298.
252. Velasco, M., et al. 2009. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J. Acquir. Immune Defic. Syndr. 50:148-152.
253. Veldsman, C., et al. 2009. QuantiFERON-TB GOLD ELISA assay for the detection of Mycobacterium tuberculosis-specific antigens in blood specimens of HIV-positive patients in a high-burden country. FEMS Immunol. Med. Microbiol. 57:269-273.
254. Vinnard, C., and R.R. Macgregor. 2009. Tuberculous meningitis in HIVinfected individuals. Curr. HIV/AIDS Rep. 6:139-145.
255. Wallis, R.S., et al. 2010. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937.
256. Weiner, M., et al. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40:1481-1491.
257. Wenning, L.A., et al. 2009. Effect of rifampin, a potent inducer of rugmetabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53:2852-2856.
258. Whalen, C., et al. 1995. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. 151:129-135.
259. Whalen, C. C., et al. 2000. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 14:1219-1228.
260. WHO. 2008. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. World Health Organization, Geneva, Switzerland.
261. WHO. 2009. Global tuberculosis control: a short update to the 2009 report. World Health Organization, Geneva, Switzerland.
262. WHO. 2009. Global tuberculosis control: epidemiology, strategy, financing. World Health Organization report 2009. World Health Organization, Geneva, Switzerland.
263. WHO. 2007. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_2007.379_eng.pdf.
264. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
265. WHO. 2009. Treatment of tuberculosis: guidelines for national programs, 4th ed. World Health Organization, Geneva, Switzerland.
266. WHO. 2007. Tuberculosis care with TB-HIV co-management-integrated management of adolescent and adult illness. World Health Organization, Geneva, Switzerland.
267. Wilson, P. 2007. Is natural ventilation a useful tool to prevent the airborne spread of TB? PLoS Med. 4:e77.
268. Wolf, A.J., et al. 2007. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J. Immunol. 179: 2509-2519.
269. Wood, R., et al. 2007. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am. J. Respir. Crit. Care Med. 175:87-93.
270. Yang, Y.F., et al. 2001. IL-12 as well as IL-2 upregulates CCR5 expression on T cell receptor-triggered human CD4 and CD8 T cells. J. Clin. Immunol. 21:116-125.
271. Yi, J.S., M. Du, and A.J. Zajac. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324:1572-1576.
272. Zagury, D., et al. 1998. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:3857-3861.
273. Zhang, Y., K. Nakata, M. Weiden, and W.N. Rom. 1995. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J. Clin. Invest. 95:2324-2331.